This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

Ticker(s): ARWR, IONS

Who's the expert?

Institution: Utah Lipid Center

  • President and Director of the Utah Lipid Center and past president of the American Board of Clinical Lipidology.
  • Treats 50 patients with hypertriglyceridemia (SHTG)
  • Responsible for writing guidelines for the American Heart Association and the American Association of Clinical Endocrinology; has co-authored over 160 scientific articles, reviews, book chapters.

Interview Goal
Discuss the significance of plozasiran and other novel drugs in FCS

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.